Pheast Therapeutics Presents Preclinical Data on PHST677, a Novel Bispecific ADC Targeting CDH1 and Nectin-4 at PEGS Boston Summit 2026

📅 11/05/2026 15:30 📰 financialcontent 👁️ 0 lectures 🌍 États-Unis 📂 Science

Preclinical data demonstrate a differentiated bispecific ADC design through E-cadherin blockade and Nectin-4 targeting